← Back to Analyst Consensus 
KNSA Buy
Kiniksa Pharmaceuticals International, plc
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 30, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Jul 29, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Jul 29, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jul 29, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 29, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 23, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Jul 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jun 29, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 29, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 29, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 29, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 29, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Apr 28, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Apr 16, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Feb 25, 2026 | Wells Fargo | maintain | Overweight → Overweight | $53 | 54% |
| Feb 25, 2026 | Wedbush | maintain | Outperform → Outperform | $53 | 58% |
| Feb 19, 2026 | Canaccord Genuity | initiate | — → Buy | $62 | 48% |
| Jan 13, 2026 | Wedbush | maintain | Outperform → Outperform | $50 | 58% |
| Oct 29, 2025 | Goldman Sachs | maintain | Buy → Buy | $55 | 54% |
| Oct 17, 2025 | Citigroup | maintain | Buy → Buy | $50 | 54% |
| Oct 13, 2025 | Wedbush | maintain | Outperform → Outperform | $44 | 58% |
| Sep 29, 2025 | TD Cowen | initiate | — → Buy | $60 | 54% |
| Sep 25, 2025 | Wells Fargo | maintain | Overweight → Overweight | $45 | 54% |
| Jul 29, 2025 | Jefferies | maintain | Buy → Buy | $54 | 52% |
| Jul 9, 2025 | Wells Fargo | maintain | Overweight → Overweight | $42 | 54% |
| Apr 29, 2025 | Jefferies | maintain | Buy → Buy | $45 | 52% |
| Apr 16, 2025 | Wedbush | reiterate | Outperform → Outperform | $34 | 58% |
| Mar 13, 2025 | Citigroup | initiate | — → Buy | $40 | 54% |
| Nov 5, 2024 | JP Morgan | maintain | Overweight → Overweight | $40 | 54% |
| Oct 30, 2024 | Evercore ISI Group | maintain | Outperform → Outperform | $35 | 58% |
| Jul 23, 2024 | Wedbush | maintain | Outperform → Outperform | $34 | 58% |
| May 3, 2024 | Wells Fargo | initiate | — → Overweight | $34 | 54% |
| May 1, 2024 | JP Morgan | maintain | Overweight → Overweight | $30 | 54% |
| Apr 24, 2024 | Evercore ISI Group | maintain | Outperform → Outperform | $30 | 58% |
| Jan 2, 2024 | Wedbush | maintain | Outperform → Outperform | $25 | 58% |
| Jul 26, 2023 | Goldman Sachs | maintain | Buy → Buy | $32 | 54% |
| Mar 9, 2023 | JP Morgan | maintain | — → Overweight | $20 | 54% |
| Dec 29, 2021 | B of A Securities | maintain | — → Buy | $34 | 53% |
| Apr 1, 2020 | B of A Securities | initiate | — → Buy | $25 | 53% |
| Mar 11, 2020 | JP Morgan | maintain | — → Overweight | $24 | 54% |
| Dec 6, 2019 | Goldman Sachs | upgrade | Neutral → Buy | $18 | 54% |
| Aug 14, 2019 | JMP Securities | maintain | — → Market Outperform | $35 | 53% |
| Mar 11, 2019 | Barclays | initiate | — → Overweight | $26 | 53% |
| Dec 12, 2018 | Wedbush | reiterate | Outperform → Outperform | $33 | 58% |
| Sep 17, 2018 | JMP Securities | maintain | Market Outperform → Market Outperform | $44 | 53% |
| Jun 18, 2018 | Goldman Sachs | initiate | — → Neutral | $22 | 54% |
| Jun 18, 2018 | Wedbush | initiate | — → Outperform | $31 | 58% |
| Jun 18, 2018 | JP Morgan | initiate | — → Overweight | $29 | 54% |
Price Target Trend
May 13, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days